NCT05922878ClinicalTrials.gov
Study of ALTO-300 in MDD
A Randomized, Double-Blind, Placebo-Controlled Study of ALTO-300 With an Open-Label Extension in Adults With Major Depressive Disorder
En bref
The purpose of this study is to determine efficacy differences between ALTO-300 and placebo, used adjunctively to an antidepressant, related to patient characteristics.
Phase 2325 participants recherchés75 sites1 pays
Catégories
Enregistré dans 1 registre
- ClinicalTrials.govNCT05922878Ouvrir cette fiche sur ClinicalTrials.govSynchronisé il y a 3 semaines
Une même étude peut être enregistrée dans plusieurs registres. Nous l'affichons une seule fois et renvoyons vers chaque fiche que nous détenons.
Les informations de l'essai sont affichées telles que publiées par le registre, dans leur langue d'origine.
Cette étude vous intéresse ?
Se connecter ou créez un compte pour manifester votre intérêt et suivre cette étude.
How this study is set up
The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.
- Not stated: Registered after enrolment began (about 20 days after the recorded start)First posted 2023-06-28; recorded start 2023-06-08
- Present: Has a defined primary outcomeA primary outcome measure is listed in the record
- Present: The primary outcome states a time frameThe primary outcome measure records a time frame
- Present: Participants are randomly assignedAllocation is recorded as randomised
- Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
- Present: Uses blinding (masking)A masking level is recorded in the record
- Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
- Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
- Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
- Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
- Present: Sponsor has 4 other studies in this databaseCounted from the lead sponsor named in the record (Alto Neuroscience)
- Not stated: No posted results from this sponsor are in this database yetBased on the sponsor’s studies in this database
- The record lists 1 condition.
- Lead sponsor type recorded as: industry.
- Intervention regulatory context: investigational, within a phased regulatory pathway.
Trial stature
Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.
A strong methodological design for a phase 2 study, judged from its ClinicalTrials.gov record.
How this score is built
- Randomised allocation20/20
Participants are randomly allocated between arms
- Blinding20/20
Quadruple-blind
- Control arm13/15
Placebo / sham control arm
- Primary-outcome specificity10/10
Named primary outcome with a defined time frame
- Endpoint type3/10
Surrogate or intermediate endpoint (conservative default)
- Multi-centre8/8
Multi-centre: 45 sites
- Data monitoring committee0/7
No data monitoring committee stated
- Prospective registration5/5
Registered before the study start date
- Protocol / SAP posted0/5
No protocol or SAP posted to the registry
A medium-sized study: 325 participants (target), run at 75 sites.
How this score is built
- Enrolment24/40
321 participants (target)
- Site count19/25
45 sites
- Country count0/15
Single country
- Planned duration8/10
Planned over about 42 months
- Sponsor scale2/10
Alto Neuroscience has led 5 trials in our corpus
We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.
How this score is built
- Investigator standing0/100
No investigator recorded in the registry for this trial
These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.
Résumé
The purpose of this study is to determine efficacy differences between ALTO-300 and placebo, used adjunctively to an antidepressant, related to patient characteristics.
Affections
- Major Depressive Disorder
Éligibilité
| Sexe | Tous |
|---|---|
| Âges | 18 Years – 70 Years |
| Volontaires sains | Non |
Éligibilité telle qu'elle figure dans le registre
Éligibilité en énoncés simples
Les critères de cette fiche n'ont pas encore été décomposés en énoncés distincts. Le texte du registre ci-dessus est complet et fait foi.
Conception de l'étude
| Type d'étude | Interventionnelle |
|---|---|
| Phase | Phase 2 |
| Répartition | Randomisée |
| Modèle d'intervention | PARALLEL |
| Objectif principal | TREATMENT |
| Insu | QUADRUPLE (4) |
| Recrutement | 325 participants recherchés |
Promoteur et collaborateurs
- Alto Neuroscience Promoteur
Groupes et interventions
- ALTO-300EXPERIMENTAL
Participants will receive ALTO-300 25mg capsule once daily in the evening, from Day 1 to Day 42 in double blind (DB) treatment period. Eligible participants who will enter the open-label (OL) treatment period will receive ALTO-300 capsule once daily in the evening from OL baseline until the end of OL period/early termination visit (Up to 8 weeks).
- PlaceboPLACEBO_COMPARATOR
Participants will receive matching placebo capsule once daily in the evening, from Day 1 to Day 42 in double blind (DB) treatment period.
Interventions
- Médicament ALTO-300
ALTO-300 capsule QD
- Médicament Placebo
Placebo capsule QD
Critères de jugement
Critère de jugement principal
To assess efficacy of adjunctive ALTO-300 versus placebo on symptoms of MDD in a pre-defined subgroup of participants as measured by the change over time up to week 6 in the Montgomery-Åsberg Depression Rating Scale (MADRS).
MADRS is a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluates the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score of 60. Higher scores represent a more severe condition.
Délai Change over time for up to week 6
Critère de jugement secondaire
To assess efficacy of adjunctive ALTO-300 versus placebo on symptoms of MDD in all randomized participants as measured by the change over time up to week 6 in the Montgomery-Åsberg Depression Rating Scale (MADRS)
MADRS is a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluates the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score of 60. Higher scores represent a more severe condition.
Délai Change over time for up to week 6
Critère de jugement secondaire
To assess efficacy of adjunctive ALTO-300 versus placebo for MDD as measured by the change over time up to week 6 in response (>50% improvement from baseline) rates based on the MADRS
MADRS is a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluates the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score of 60. Higher scores represent a more severe condition.
Délai Change over time for up to week 6
Critère de jugement secondaire
To evaluate the safety of ALTO-300 during both the OL and DB periods of the study as measured by the assessment of the incidence, severity, and relatedness of Adverse Events.
Incidence, severity, and relatedness of Adverse Events
Délai Assessed from Day 1 to Week 14
Critère de jugement secondaire
To evaluate the safety of ALTO-300 during both the OL and DB periods of the study as measured by the assessment of Heart Rate.
Assessment of Heart Rate
Délai Assessed from Day 1 to Week 14
Critère de jugement secondaire
To evaluate the safety of ALTO-300 during both the OL and DB periods of the study as measured by the assessment of Weight.
Assessment of Weight Change
Délai Assessed from Day 1 to Week 14
Critère de jugement secondaire
To evaluate the safety of ALTO-300 during both the OL and DB periods of the study as measured by the assessment of Blood Pressure.
Assessment of Blood Pressure
Délai Assessed from Day 1 to Week 14
Critère de jugement secondaire
To evaluate the safety of ALTO-300 during both the OL and DB periods of the study as measured by the assessment of suicidality with the Concise Health Risk Tracking Self-Report,12 item scale (CHRT-SR12).
The CHRT is a brief, self-report measure that systematically assesses both suicidal thinking and associated thoughts that may indicate the propensity for suicidal acts. The CHRT-SR12 is a 12 item scale. The patient assigns a score of 0-4 for each item of the scale, allowing for a total score of 0 to 48, with the higher score signifying more severe symptoms.
Délai Assessed from Day 1 to Week 15
Dates
| Date de début | 8 juin 2023 (réelle) |
|---|---|
| Achèvement principal | 1 décembre 2026 (estimée) |
| Achèvement | 1 décembre 2026 (estimée) |
| Première publication | 28 juin 2023 (réelle) |
| Dernière mise à jour | 26 octobre 2026 |
| Résultats publiés | Non précisé dans la fiche du registre |
| Statut vérifié pour la dernière fois | octobre 2026 |
Réelle signifie que l'événement a eu lieu. Estimée signifie que le promoteur s'y attend. Les deux ont un sens différent.
Lieux
30 sites sont en recrutement
United States
| Établissement | Ville | État ou région | Statut |
|---|---|---|---|
| Site 114 | Albuquerque | New Mexico | En recrutement |
| Site 216 | Allentown | Pennsylvania | Arrêté prématurément |
| Site 316 | Austin | Texas | En recrutement |
| Site 218 | Bellflower | California | En recrutement |
| Site 317 | Blackfoot | Idaho | Retiré |
| Site 236 | Boise | Idaho | En recrutement |
| Site 119 | Boise | Idaho | Actif, sans recrutement |
| Site 318 | Carlsbad | California | Actif, sans recrutement |
| Site 310 | Chicago | Illinois | Actif, sans recrutement |
| Site 202 | Cincinnati | Ohio | En recrutement |
| Site 159 | Clermont | Florida | Arrêté prématurément |
| Site 207 | Clinton | Utah | Actif, sans recrutement |
| Site 203 | Colorado Springs | Colorado | Actif, sans recrutement |
| Site 239 | Conroe | Texas | En recrutement |
| Site 229 | Creve Couer | Missouri | Retiré |
| Site 102 | Dallas | Texas | Actif, sans recrutement |
| Site 343 | Denver | Colorado | En recrutement |
| Site 349 | Evergreen | Colorado | Actif, sans recrutement |
| Site 345 | Evergreen | Colorado | Actif, sans recrutement |
| Site 277 | Fairfax | Virginia | En recrutement |
| Site 238 | Fayetteville | Georgia | En recrutement |
| Site 148 | Fort Worth | Texas | Retiré |
| Site 347 | Fort Worth | Texas | Arrêté prématurément |
| Site 217 | Glendale | California | Actif, sans recrutement |
| Site 279 | Hattiesburg | Mississippi | Retiré |
| Site 199 | Hickory | North Carolina | Actif, sans recrutement |
| Site 320 | Houston | Texas | En recrutement |
| Site 275 | Houston | Texas | En recrutement |
| Site 215 | Jackson | Mississippi | Actif, sans recrutement |
| Site 335 | Lafayette | California | En recrutement |
| Site 335 | Lafayette | California | En recrutement |
| Site 344 | Las Vegas | Nevada | En recrutement |
| Site 209 | Los Angeles | California | Actif, sans recrutement |
| Site 240 | Mankato | Minnesota | En recrutement |
| Site 201 | Marrero | Louisiana | Arrêté prématurément |
| Site 219 | Mather | California | En recrutement |
| Site 350 | Media | Pennsylvania | Retiré |
| Site 225 | Miami Gardens | Florida | Actif, sans recrutement |
| Site 190 | Miami Lakes | Florida | Actif, sans recrutement |
| Site 265 | Minneapolis | Minnesota | En recrutement |
| Site 194 | Mission Viejo | California | Arrêté prématurément |
| Site 206 | Missouri City | Texas | Retiré |
| Site 198 | Monroe | Louisiana | Arrêté prématurément |
| Site 267 | Moorpark | California | En recrutement |
| Site 352 | Moosic | Pennsylvania | Actif, sans recrutement |
| Site 283 | New York | New York | En recrutement |
| Site 319 | New York | New York | Actif, sans recrutement |
| Site 214 | Norwalk | Connecticut | Retiré |
| Site 161 | Okeechobee | Florida | Actif, sans recrutement |
| Site 195 | Oklahoma City | Oklahoma | Arrêté prématurément |
25 sites supplémentaires sont indiqués dans la fiche du registre.
Documents de l'étude
Aucun document n'est lié dans cette fiche du registre.
Évolution au fil du temps
- 26 octobre 2026
Objectif de recrutement modifié
Enrollment target revised up from 321 to 325
321325
- 26 octobre 2026
Site ajouté
30 sites added (75 total)
4575